title: Management of autoimmune diseases after haematopoietic stem cell transplantation.
abstract: Autologous and allogeneic haematopoietic stem cell transplantation (HSCT) is an option for the treatment of malignant and non-malignant diseases, including the severe autoimmune diseases. Intriguingly, the 'new' autoimmunity developing after transplantation is a constantly recognized phenomenon, which has to be differentiated from original disease relapse, toxicity, infection and graft-versus-host disease. The reported autoimmune diseases occurring in this setting are mainly antibody-associated and organ-specific, with scarce evidence in support for specific treatment options. This review focuses on current concepts on the pathogenesis, the available data on incidence, risk factors, manifestations and treatment of post-HSCT autoimmune diseases.
authors.affiliation: Clinic of Haematology, University Hospital, Basel, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Holbro
authors.forename: Mario
authors.initials: M
authors.lastname: Abinun
authors.forename: Thomas
authors.initials: T
authors.lastname: Daikeler
mesh_terms: D001327:Autoimmune Diseases / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology / Q000628:therapy*; D003937:Diagnosis, Differential; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D015994:Incidence; D011379:Prognosis; D012307:Risk Factors